Product Overview
Structure
1 caps. Lyophilized bacteria lysate:
Streptococcus pneumoniae,
Haemophilus influenzae,
Klebsiella pneumoniae,
Klebsiella ozaenae,
Staphylococcus aureus,
Streptococcus viridans,
Streptococcus pyogenes,
Moraxella catarrhalis 7 mg
Excipients:
propyl gallate (anhydrous),
sodium glutamate (anhydrous),
mannitol
magnesium stearate,
pregelatinized starch
indigotine
titanium dioxide
gelatin.
pharmachologic effect
Immunomodulating drug of bacterial origin.
It stimulates both the local cellular and humoral immune response in the mucous membrane of the respiratory tract, as well as the systemic immune response.
The drug stimulates the activity of alveolar macrophages, increases the number and activity of T-lymphocytes, activates peripheral monocytes, increases the concentration of secretory IgA on the mucous membranes of the respiratory tract and digestive tract, stimulates the production of protective adhesive molecules, reduces the concentration of IgE antibodies in the blood, and also increases the production of cytokines.
Reduces the frequency and severity of infections, thereby reducing the need for antibiotics.
Indications
- infectious diseases of the respiratory tract (as part of complex therapy as an immunomodulating agent) in children aged 6 months to 12 years (for 3.5 mg capsules);
- infectious diseases of the respiratory tract (as part of complex therapy as an immunomodulating agent) in adults and children over the age of 12 years (for capsules 7 mg);
- for the prevention of recurrent infections of the upper and lower respiratory tract (chronic bronchitis, tonsillitis, pharyngitis, laryngitis, rhinitis, sinusitis, otitis media).
Contraindications
Increased individual sensitivity to the components of the drug.
Side effects
During the entire period of clinical use of the drug, undesirable effects were recorded extremely rarely.
In some cases: disorders of the digestive system (epigastric pain, nausea, vomiting, diarrhea), fever.
If side effects are mild, discontinuation of the drug is not required. When a hypersensitivity reaction occurs, drug withdrawal is recommended.
Interaction
The drug can be used simultaneously with other drugs, including antibiotics.
How to take, course of administration and dosage
Adults and children over 12 years of age: Broncho-munal® is prescribed in a dose of 7 mg; children aged 6 months to 12 years are prescribed Broncho-munal® P at a dose of 3.5 mg.
The drug is taken in the morning on an empty stomach at 1 caps./day. If the patient / child cannot swallow the capsule, it is recommended to open it, and dissolve the contents of the capsule in a small amount of liquid (tea, milk or juice).
For the prevention of infectious diseases of the respiratory tract: the drug is used in three 10-day courses with 20-day intervals between them.
In the acute period of the disease: 1 capsule / day is prescribed until the symptoms of the disease disappear, but not less than 10 days. In the next 2 months, the prophylactic use of the drug in 1 capsule is possible. for 10 days with a 20-day interval between courses.
Overdose
No clinical symptoms of overdose were noted. There are no reports of intoxication due to an overdose of the drug.
Special instructions
A 4-week interval should be observed between the use of oral vaccines and the administration of Broncho-munal.
It is not recommended to use the drug for acute intestinal diseases due to a possible decrease in the effectiveness of the drug.
Pediatric Use
The drug is not prescribed for children under the age of 6 months. To avoid overdose, children from 6 months to 12 years of age are prescribed only Broncho-munal® P (capsules containing 3.5 mg of lyophilisate).
Influence on the ability to drive vehicles and control mechanisms
No special precautions required.
Release form
Hard gelatin capsules, size No. 3, opaque, with a body and a lid of blue color; capsule contents - light beige powder.